Abbott Laboratories $ABT Shares Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. raised its holdings in shares of Abbott Laboratories (NYSE:ABT) by 303.0% in the first quarter, Holdings Channel.com reports. The firm owned 4,429,571 shares of the healthcare product maker’s stock after buying an additional 3,330,368 shares during the period. Abbott Laboratories comprises 0.7% of Assenagon Asset Management S.A.’s portfolio, making the stock its 22nd largest holding. Assenagon Asset Management S.A.’s holdings in Abbott Laboratories were worth $454,784,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Brighton Jones LLC boosted its holdings in Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after purchasing an additional 4,755 shares during the period. Sivia Capital Partners LLC boosted its holdings in shares of Abbott Laboratories by 3.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after buying an additional 162 shares during the period. United Bank grew its position in shares of Abbott Laboratories by 7.4% during the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after buying an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC raised its stake in Abbott Laboratories by 13.6% during the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock worth $1,618,000 after acquiring an additional 1,428 shares during the period. Finally, Canada Pension Plan Investment Board lifted its holdings in Abbott Laboratories by 25.6% in the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock worth $195,267,000 after acquiring an additional 292,547 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Daniel J. Starks bought 10,000 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were acquired at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Philip P. Boudreau purchased 2,200 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, April 23rd. The stock was purchased at an average price of $91.50 per share, with a total value of $201,300.00. Following the transaction, the chief financial officer owned 2,200 shares in the company, valued at $201,300. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Barclays reduced their price objective on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research report on Monday, April 20th. Weiss Ratings downgraded shares of Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, June 16th. Sanford C. Bernstein dropped their price objective on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Piper Sandler reiterated an “overweight” rating and issued a $115.00 price objective on shares of Abbott Laboratories in a research report on Monday. Finally, TD Cowen dropped their price target on shares of Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average price target of $118.30.

Abbott Laboratories Trading Up 3.0%

Shares of ABT stock opened at $90.44 on Wednesday. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The stock has a 50-day simple moving average of $89.59 and a 200 day simple moving average of $105.93. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $139.06. The stock has a market capitalization of $157.53 billion, a P/E ratio of 25.33, a P/E/G ratio of 1.51 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. During the same period in the prior year, the business earned $1.09 earnings per share. The business’s quarterly revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, sell-side analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.8%. Abbott Laboratories’s dividend payout ratio is currently 70.59%.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott was highlighted by TipRanks as one of three dividend aristocrat stocks Wall Street currently likes, reinforcing its appeal as a defensive, income-oriented name. 3 Dividend Aristocrat Stocks Wall Street Loves Right Now — June 23, 2026
• Positive Sentiment: Piper Sandler reaffirmed its Overweight rating and kept a $115 price target on Abbott, signaling meaningful upside from current levels. Benzinga report on Piper Sandler rating
• Positive Sentiment: Abbott’s Similac brand launched a new “Love Without Measure” campaign aimed at supporting parents and strengthening brand engagement in infant nutrition. Abbott (ABT) Launches Similac Campaign To Ease Social Media Pressure On Young Parents
• Positive Sentiment: Analysts continue to view Abbott favorably overall, with consensus still at “Moderate Buy,” which supports the stock’s recent rebound. Abbott Laboratories (NYSE:ABT) Receives Consensus Recommendation of “Moderate Buy” from Analysts
• Neutral Sentiment: Several articles note that ABT has attracted investor attention, but these pieces are largely traffic-driven and do not add new fundamental information. Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Commentary on Abbott’s sharp year-to-date decline points to existing headwinds such as respiratory testing weakness, China uncertainty, and acquisition dilution, but does not introduce a new catalyst. How to Approach Abbott Stock Following Its Sharp YTD Decline?
• Negative Sentiment: A Missouri appeals court declined to elevate Abbott’s appeal of a $495 million preterm baby formula verdict, leaving a large legal liability in place and likely weighing on sentiment. Missouri appeals court won’t send Abbott’s appeal of $495 million preterm baby formula verdict to higher court

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.